Business Wire

SkyKick Releases Major Platform Upgrades with New Intelligent Cloud Backup Product, Revamped Security Manager, and Next-Generation Migration Suites

Share

SkyKick (https://www.skykick.com), a global leader in cloud automation and management solutions for information technology service providers (ITSPs), today announced major enhancements to its Cloud Management Platform. New products and updates deliver enhanced data protection capabilities and personalized security insights, enabling ITSPs to meet the growing demand for robust security solutions and conversations in the SMB market. This marks the biggest platform update in the company’s ten-year history.

In an era dominated by data and AI, security is a top concern for 88% of SMB customers. Despite overall IT budgets staying flat or even declining, 42% of SMB business owners are open to investing more in security and data protection solutions. SMB appetite for MSP security services continues to grow against the backdrop of increased Microsoft 365 adoption (now with an estimated 382 million commercial users worldwide) and the proliferation of sensitive data that is being created in the cloud. ITSPs are struggling to meet demand.

“As pioneers in Microsoft 365 cloud data protection and security, we closely monitor usage and adoption trends among customers and partners," said SkyKick Co-CEO Todd Schwartz. "We’re seeing that in order for ITSPs to turn customer appetite into a successful security and data protection business, they need better and more intelligent tools. Our new products make it easy for ITSPs to not only meet customer demand, but also build a successful security practice – one that is easy to sell and easy to manage."

SkyKick is announcing a reimagined Cloud Backup product, offering Intelligent Data Protection for Microsoft 365. Among the exciting new features is SmartInsights, a new capability that enhances customer engagements through insights on data growth and protection trends. Today, customers are proactively seeking to understand their data protection status. With SmartInsights, ITSPs can tap into this customer appetite and transform data protection into a valuable differentiator.

Beyond SmartInsights, the new Cloud Backup introduces a user-centric architecture that streamlines ease of use for ITSPs. Examples include a new Groups Management functionality, which scales onboarding and offboarding processes. Extending the comprehensive Microsoft 365 coverage, protection for Microsoft Planner data is now also included. Collectively, the new Cloud Backup reimagines data protection for the modern ITSP, reducing time to resolution and increasing customer satisfaction.

Additionally, SkyKick has revamped its Security Manager solution, which now has millions of SMB end-users under management since its debut in the fall of 2022.

“For partners to fully deliver on the customer promise, they need to go beyond data protection. We created Security Manager to help partners be more proactive on security and grow a stronger practice,” said SkyKick Co-CEO Evan Richman. “Today, SkyKick is announcing SecurityRadar, a key innovation within Security Manager, purpose-built to arm 100,000 Microsoft cloud partners with data-driven security insights they can use to drive proactive and personalized customer engagement.”

Beyond SecurityRadar, Security Manager is upgrading its proprietary Microsoft Partner Center Connector (PCI) with new sync technology that is 2X faster and more automated - further simplifying day-to-day customer management and Microsoft-mandated GDAP compliance.

Early market reaction to the new updates has been very positive.

“Security is a top priority for Kinetix and New Charter Technologies. We are excited about the new innovations in Security Manager, and SecurityRadar is a game-changer for us,” said Robert Herbaugh, Security and Strategy Specialist at a leading MSP. “By facilitating strong customer conversations on security, it is helping us drive increased customer value and revenue growth.”

SkyKick is also announcing the next major version of its industry-leading Migration Suites. Between a streamlined setup, a more performant sync technology, and a highly configurable new migration experience – SkyKick has reimagined the “easiest way to Microsoft 365” with even more ease, flexibility, and control for the modern ITSP.

ITSPs, as well as their customers, deserve the assurance of knowing that their technology itself is certified to be robust and enterprise-grade. Building on its numerous other certifications, the SkyKick platform and system is now certified for ISO 27001, ISO 27701 and Data Pro.

SkyKick Co-CEO Evan Richman noted, “Our fundamental vision remains to be the platform of choice for ITSPs building and growing a business around Microsoft 365. With the major enhancements that we are announcing now across Migrations, Backup, Security Manager, and Certifications, we are confident that SkyKick will help IT partners to stay ahead of challenges and deliver a truly differentiated value in the channel.”

About SkyKick

SkyKick is a global provider of cloud management software for IT Services Providers. The company is headquartered in Seattle, Wash., and has offices in Amsterdam, Sydney, and Tokyo. Its products are designed to help build successful cloud businesses by making it easy and efficient for IT providers to migrate, backup, manage and secure their customers in the cloud. Over 30,000 partners worldwide use SkyKick’s products to accelerate their cloud business, and the company has won numerous awards including being named a Microsoft Partner of the Year, 2023 IAMCP Partner of the Year, Red Herring Top 100 North America winner and one of the “100 Best Companies to Work For” in Washington State. For more information visit www.skykick.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Forecki
Voxus PR for SkyKick
skykickpr@voxuspr.com
253.208.3615

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye